Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (23245)	7/15/1998 3:55:00 PM
From: Henry Niman	Respond to of 32384

Alper, For breast cancer there is no shortage of patients, so the accruals should go fairly smoothly. Phase II trials are primarily designed to determine the appropriate concentration for treating a larger Phase III population. I suspect that the phase II trial would take 6-12 months once it got started, which I suspect will be fairly soon. I'm assuming that LGND will conduct a reasonable large multi-center trial. I would guess that Phase III would take 1-3 years. However, I expect Targretin to be approved for CTCL before the Phase II trial is completed and if the Phase II breast cancer data is encouraging, I would expect off label use to begin shortly after the Phase II data is compiled. LGND has many partners in the clinic and I expect the news to be spread rather rapidly. I believe that Targretin is already in use on a compassionate basis for several advanced cancers.